Aluminum Hydroxide Magnesium Hydroxide

證據等級: L5

預測適應症: 0 個

Aluminum Hydroxide + Magnesium Hydroxide: Repurposing Evaluation — Insufficient Data to Proceed

One-Sentence Summary

Aluminum hydroxide combined with magnesium hydroxide is a well-known antacid combination used for acid-related gastrointestinal conditions. The TxGNN pipeline returned no predicted indications for this drug, and the Evidence Pack contains no market authorization records and no safety data, making a repurposing assessment impossible at this stage. This report documents the data gaps and recommends remediation steps before re-evaluation.

Quick Overview

Item	Content
Original Indication	Not recorded in this Evidence Pack
Predicted New Indication	No prediction generated
TxGNN Prediction Score	N/A
Evidence Level	Not assessable (no predictions)
Market Status	Not marketed (0 authorizations found)
Number of Authorizations	0
Recommended Decision	Hold

Why the Pipeline Returned No Predictions

The pipeline was unable to produce repurposing candidates for this drug for the following likely reasons:

DrugBank ID is missing. The Evidence Pack records drugbank_id: null, meaning the TxGNN knowledge graph could not link this drug to a graph node. Without a valid DrugBank node, the knowledge graph traversal and deep-learning scoring steps cannot run, producing an empty predicted_indications array.

The drug name is a compound string. The query used "ALUMINUM HYDROXIDE; MAGNESIUM HYDROXIDE" as a single token. Most mapping pipelines expect individual INN names. The semicolon-delimited format may have caused the normalizer to fail to match either component to a DrugBank entry.

Market data absence may be an artefact. Aluminum hydroxide/magnesium hydroxide combination products (e.g., Maalox, Mylanta) are widely sold OTC in most markets. Zero authorizations is likely a retrieval miss — possibly because OTC products use different registration pathways — rather than genuine absence from the market.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN predictions were generated because the DrugBank mapping failed, making the knowledge-graph and deep-learning steps inoperable. There is no candidate indication to evaluate, and all safety fields are flagged as data gaps.

To proceed, the following is needed:

Resolve DG002 (High) — Identify DrugBank IDs for both components
- Aluminum hydroxide: DB01592 (DrugBank)
- Magnesium hydroxide: DB14021 (DrugBank)
- Update the pipeline to pass each component separately, then merge predictions.
Resolve DG001 (Blocking) — Obtain package insert warnings and contraindications
- Source: Regulatory authority official website
- Method: Download and parse the package insert PDF.
Verify market registration status
- Confirm whether OTC registrations are captured in the current data source; if not, extend the query to OTC/over-the-counter databases.
Re-run TxGNN pipeline
- After DrugBank IDs are confirmed, re-run run_kg_prediction.py and txgnn_model.py for each individual component (aluminum hydroxide and magnesium hydroxide), then generate the combined Evidence Pack.
Consider evaluating components individually
- Literature and clinical trial evidence for antacid repurposing (e.g., aluminum hydroxide in hyperphosphatemia, magnesium hydroxide as a laxative) exists and may surface meaningful TxGNN candidates once properly mapped.
  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.